DGX Quest Diagnostics Incorporated Common Stock
NYSE · Health Care · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Jul 23, 2026
$233.33
· of 52w range
· above low
· to high
$171.1852w low
$248.8452w high
Market Cap (MRQ)
$25.67B
P/E (TTM)
24.8
EPS (TTM)
$9.42
Revenue (TTM)
$11.56B
your badges
52W Range
$171–$249
Analyst Rating
HOLD
Price Target
$248
P/E
24.8
ROE
14.4%
Net Profit Margin
9.2%
Your badge strip is empty — pin a metric anywhere on this page.
DGX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$233.33
Market Cap (MRQ)
$25.67B
P/E (TTM)
24.8
EPS (TTM)
$9.42
Revenue (TTM)
$11.56B
Div Yield
1.4%
ROE (TTM)
14.4%
Debt/Equity (MRQ)
0.8
52W Range
$171–$249
DGX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| June 21, 2005 | 2-for-1 | Forward |
| June 1, 2001 | 2-for-1 | Forward |
About Quest Diagnostics Incorporated Common Stock Company overview from Wikipedia
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealth Care
industryHealth Care
employees46,000
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$11.04B2016-12-31 → 2025-12-31
EPS$8.752016-12-31 → 2025-12-31
Free Cash Flow$1.36B2016-12-31 → 2025-12-31
Net margin9.2%2016-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | DGX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 24.85Y avg ≈17.7 | ≈17.7 | 23.3 | Undervalued | |
| P/S (TTM) | 2.25Y avg ≈1.7 | ≈1.7 | 1.3 | Overvalued | |
| P/B (MRQ) | 3.45Y avg ≈2.7 | ≈2.7 | 2.9 | Fair value | |
| EV / EBITDA | 14.75Y avg ≈11.0 | ≈11.0 | 11.4 | Fair value | |
| Price / FCF (TTM) | 19.05Y avg ≈14.9 | ≈14.9 | · | · | |
| Price / Cash Flow (TTM) | 13.55Y avg ≈10.8 | ≈10.8 | 9.8 | Fair value | |
| EV / Revenue | 2.85Y avg ≈2.2 | ≈2.2 | · | · | |
| EV / FCF | 22.95Y avg ≈18.8 | ≈18.8 | · | · | |
| Price / Tangible Book (MRQ) | 4.4 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | DGX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 14.1%5Y avg ≈15.6% | ≈15.6% | 8.3% | Top tier | |
| EBITDA Margin (TTM) | 19.1%5Y avg ≈20.2% | ≈20.2% | 8.8% | Top tier | |
| Pretax Margin (TTM) | 12.1%5Y avg ≈14.5% | ≈14.5% | 3.8% | Top tier | |
| Net Profit Margin (TTM) | 9.2%5Y avg ≈11.0% | ≈11.0% | 5.1% | Top tier | |
| ROA (TTM) | 6.5%5Y avg ≈8.0% | ≈8.0% | 4.0% | Top tier | |
| ROE (TTM) | 14.4%5Y avg ≈17.4% | ≈17.4% | 12.5% | In line | |
| ROIC | 9.2%5Y avg ≈11.0% | ≈11.0% | 9.2% | In line |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | DGX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.85Y avg ≈0.8 | ≈0.8 | 0.4 | High debt | |
| Current Ratio (MRQ) | 1.65Y avg ≈1.2 | ≈1.2 | 1.4 | Strong liquidity | |
| Quick Ratio | 0.85Y avg ≈1.0 | ≈1.0 | 0.8 | Strong liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.75Y avg ≈0.7 | ≈0.7 | 0.7 | High debt |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | DGX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 11.8%5Y avg ≈3.6% | ≈3.6% | · | · | |
| Revenue CAGR 3Y | 3.7%5Y avg ≈0.06% | ≈0.06% | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | |
| EPS YoY | 13.8%5Y avg ≈2.0% | ≈2.0% | · | · | |
| Net Income YoY | 13.9%5Y avg ≈-1.4% | ≈-1.4% | · | · | |
| EPS CAGR 3Y | 3.2%5Y avg ≈-9.4% | ≈-9.4% | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | |
| Net Income CAGR 3Y | 1.6%5Y avg ≈-12.8% | ≈-12.8% | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | DGX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.75Y avg ≈0.7 | ≈0.7 | 1.2 | Weak | |
| Inventory Turnover | 39.15Y avg ≈33.9 | ≈33.9 | 15.6 | Top tier | |
| Receivables Turnover | 8.15Y avg ≈7.7 | ≈7.7 | 10.5 | Weak | |
| Revenue / Employee | ≈$239.9K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
Dividend Yield1.4%
Payout Ratio35.6%
Annualized Payout≈$3.44
5Y Div CAGR≈7.4%
Growth Streak≈14
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Jul 8, 2026 | $0.86 | USD | ≈1.6% |
| Apr 6, 2026 | $0.86 | USD | ≈1.6% |
| Jan 13, 2026 | $0.80 | USD | ≈1.8% |
| Oct 3, 2025 | $0.80 | USD | ≈1.8% |
| Jul 7, 2025 | $0.80 | USD | ≈1.8% |
| Apr 7, 2025 | $0.80 | USD | ≈1.9% |
| Jan 14, 2025 | $0.75 | USD | ≈2.0% |
| Oct 4, 2024 | $0.75 | USD | ≈2.0% |
| Jul 8, 2024 | $0.75 | USD | ≈2.1% |
| Apr 5, 2024 | $0.75 | USD | ≈2.2% |
| Jan 16, 2024 | $0.71 | USD | ≈2.1% |
| Oct 5, 2023 | $0.71 | USD | ≈2.3% |
| Jul 10, 2023 | $0.71 | USD | ≈2.0% |
| Apr 6, 2023 | $0.71 | USD | ≈1.9% |
| Jan 17, 2023 | $0.66 | USD | ≈1.8% |
| Oct 3, 2022 | $0.66 | USD | ≈2.1% |
| Jul 5, 2022 | $0.66 | USD | ≈1.9% |
| Apr 5, 2022 | $0.66 | USD | ≈1.9% |
| Jan 18, 2022 | $0.62 | USD | ≈1.8% |
| Oct 4, 2021 | $0.62 | USD | ≈1.7% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
3.6%
Next Report
Oct 19, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Jul 20, 2026 | $3.12 | $2.85 | 9.3% |
| March 31, 2026 | $2.50 | $2.37 | 5.5% | |
| Dec. 31, 2025 | $2.42 | $2.38 | 1.5% | |
| Sept. 30, 2025 | $2.60 | $2.53 | 2.8% | |
| June 30, 2025 | $2.62 | $2.60 | 0.93% | |
| March 31, 2025 | $2.21 | $2.17 | 1.7% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $65.18 | $61.06 | $56.82 | $53.09 | $54.15 | $50.82 | $42.41 | $38.64 | $36.45 | $33.78 | $32.76 | $29.87 | |
| Revenue / Share | $97.65 | $87.36 | $81.88 | $83.75 | $84.28 | $69.39 | $56.81 | $54.18 | $55.06 | $52.92 | $51.68 | $51.28 | |
| Cash Flow / Share | $16.69 | $11.81 | $11.26 | $14.56 | $17.45 | $14.74 | $9.14 | $8.63 | $8.39 | $7.53 | $5.59 | $6.47 | |
| Cash / Share | $3.82 | $4.95 | $6.18 | $2.84 | $7.33 | $8.71 | $8.96 | $1.00 | $1.01 | $2.62 | $0.93 | $1.33 | |
| Dividend / Share | · | · | · | · | · | · | · | · | $1.80 | $1.65 | $1.52 | $1.32 | |
| EPS (TTM) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | · | 112,000,000 | 112,000,000 | 111,000,000 | · | 112,000,000 | 111,000,000 | 111,000,000 | · | 112,000,000 | 112,000,000 | 112,000,000 | · | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | · | 113,000,000 | 113,000,000 | 113,000,000 | · | 113,000,000 | 112,000,000 | 112,000,000 | · | 114,000,000 | 114,000,000 | 113,000,000 | · | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $68.33 | $66.36 | · | $65.39 | $64.54 | $61.87 | · | $60.79 | $59.61 | $57.95 | · | $57.37 | $55.79 | $54.02 | · | $54.69 | |
| Revenue / Share | $27.17 | $25.85 | · | $24.92 | $24.43 | $23.47 | · | $22.02 | $21.40 | $21.12 | · | $20.13 | $20.51 | $20.63 | · | $21.07 | |
| Cash Flow / Share | · | $2.48 | · | · | · | $2.78 | · | · | · | $1.38 | · | · | · | $0.83 | · | · | |
| Cash / Share | $5.69 | $3.54 | · | $3.89 | $2.85 | $1.68 | · | $6.82 | $2.44 | $4.27 | · | $1.28 | $1.12 | $1.56 | · | $6.14 | |
| Dividend / Share | $0.86 | $0.86 | $0.80 | $0.80 | $0.80 | $0.80 | $0.75 | $0.75 | $0.75 | $0.75 | $0.71 | $0.71 | $0.71 | $0.71 | $0.66 | $0.66 | |
| EPS (TTM) | $9.42 | $9.05 | · | $8.52 | $8.35 | $7.91 | · | $7.44 | $7.41 | $7.43 | · | $6.71 | $6.92 | $6.83 | · | $10.16 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.56B | $11.28B | · | $10.85B | $10.52B | $10.16B | · | $9.54B | $9.35B | $9.29B | · | $9.30B | $9.49B | $9.60B | · | $10.29B | |
| Net Income TTM | $1.06B | $1.02B | · | $969M | $950M | $897M | · | $841M | $840M | $846M | · | $763M | $794M | $793M | · | $1.24B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 22.5 | 21.7 | · | 22.4 | 21.5 | 21.4 | · | 20.9 | 18.5 | 17.9 | · | 18.2 | 20.3 | 20.7 | · | 12.1 | |
| P/S | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.5 | 1.7 | 1.7 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 2.0 | 1.9 | 1.8 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Dividend Yield | 1.6% | 1.6% | · | 1.6% | 1.7% | 1.8% | · | 1.9% | 2.1% | 2.2% | · | 2.3% | 1.9% | 1.9% | · | 2.2% | |
| Earnings Yield | 4.4% | 4.6% | · | 4.5% | 4.7% | 4.7% | · | 4.8% | 5.4% | 5.6% | · | 5.5% | 4.9% | 4.8% | · | 8.3% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · | |
| Annual Payout | $363M | $357M | · | $347M | $342M | $336M | · | $327M | $323M | $319M | · | $309M | $307M | $305M | · | $307M |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Operating Margin % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Net Income | $992M | $871M | $854M | $946M | $2.00B |
| Diluted EPS | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B |
Institutional owners (13F) 1,170 filers · $23.1B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
1,170
Value held
$23.1B
New positions
118
Exited positions
64
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 118 (-23 vs prior Q) | 64 (-18 vs prior Q) | 430 (+89 vs prior Q) | 343 (-26 vs prior Q) | +3.8M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $2,497,458,052 | 14,392,082 | 10.79% | Shares |
| BlackRock, Inc. | $1,965,923,399 | 9,275,411 | 8.49% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,533,117,858 | 7,233,394 | 6.62% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,299,474,988 | 6,131,045 | 5.61% | Shares |
| STATE STREET CORP | $1,169,252,484 | 5,516,643 | 5.05% | Shares |
| Boston Partners | $1,004,552,880 | 4,744,473 | 4.34% | Shares |
| JPMORGAN CHASE & CO | $748,586,197 | 3,520,438 | 3.23% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $662,582,607 | 3,137,873 | 2.86% | Shares |
| MORGAN STANLEY | $521,503,271 | 2,460,497 | 2.25% | Shares |
| EdgePoint Investment Group Inc. | $476,372,038 | 2,247,568 | 2.06% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $421,376,156 | 1,988,048 | 1.82% | Shares |
| BANK OF AMERICA CORP /DE/ | $410,151,497 | 1,935,133 | 1.77% | Shares |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400,206,122 | 1,888,207 | 1.73% | Shares |
| WELLS FARGO & COMPANY/MN | $371,171,119 | 1,751,220 | 1.60% | Shares |
| Davis Selected Advisers | $329,781,509 | 1,555,612 | 1.42% | Shares |
| VICTORY CAPITAL MANAGEMENT INC | $311,037,928 | 1,467,506 | 1.34% | Shares |
| NORGES BANK | $298,133,109 | 1,406,620 | 1.29% | Shares |
| FMR LLC | $296,462,102 | 1,398,735 | 1.28% | Shares |
| Invesco Ltd. | $292,303,423 | 1,379,115 | 1.26% | Shares |
| NORTHERN TRUST CORP | $238,963,873 | 1,127,454 | 1.03% | Shares |
| GOLDMAN SACHS GROUP INC | $208,282,052 | 982,694 | 0.90% | Shares |
| UBS Group AG | $188,403,627 | 888,906 | 0.81% | Shares |
| AMERICAN CENTURY COMPANIES INC | $173,422,135 | 818,220 | 0.75% | Shares |
| M&G PLC | $168,677,800 | 795,650 | 0.73% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $165,917,256 | 846,603 | 0.72% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $163,988,047 | 773,711 | 0.71% | Shares |
| AMERIPRISE FINANCIAL INC | $161,076,730 | 759,975 | 0.70% | Shares |
| Legal & General Group Plc | $151,986,161 | 717,085 | 0.66% | Shares |
| Bank of New York Mellon Corp | $133,388,337 | 629,339 | 0.58% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $131,756,386 | 621,639 | 0.57% | Shares |
| DEUTSCHE BANK AG\ | $124,180,445 | 585,895 | 0.54% | Shares |
| ALLIANCEBERNSTEIN L.P. | $122,662,706 | 625,894 | 0.53% | Shares |
| Nuveen, LLC | $119,503,667 | 563,830 | 0.52% | Shares |
| PRINCIPAL FINANCIAL GROUP INC | $109,630,811 | 517,225 | 0.47% | Shares |
| RAYMOND JAMES FINANCIAL INC | $107,196,222 | 505,762 | 0.46% | Shares |
| Amundi | $105,710,274 | 498,751 | 0.46% | Shares |
| Woodline Partners LP | $102,974,000 | 485,841 | 0.44% | Shares |
| FIDUCIARY MANAGEMENT INC /WI/ | $102,489,906 | 483,557 | 0.44% | Shares |
| Artemis Investment Management LLP | $99,175,856 | 467,921 | 0.43% | Shares |
| CRAWFORD INVESTMENT COUNSEL INC | $97,514,204 | 460,081 | 0.42% | Shares |
| BARCLAYS PLC | $95,107,474 | 448,726 | 0.41% | Shares |
| ENVESTNET ASSET MANAGEMENT INC | $90,834,224 | 428,564 | 0.39% | Shares |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $88,822,918 | 417,715 | 0.38% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $83,772,178 | 395,245 | 0.36% | Shares |
| M.D. Sass, LLC | $76,397,960 | 360,453 | 0.33% | Shares |
| Qube Research & Technologies Ltd | $72,783,206 | 343,398 | 0.31% | Shares |
| MACKENZIE FINANCIAL CORP | $70,641,875 | 333,295 | 0.31% | Shares |
| Advisors Capital Management, LLC | $69,429,626 | 327,575 | 0.30% | Shares |
| CITIGROUP INC | $66,888,058 | 315,584 | 0.29% | Shares |
| Swiss National Bank | $65,683,305 | 309,900 | 0.28% | Shares |
Activists & 5%+ owners 13 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | May 18, 2011 | · | Initial filing | M&A / sale | SEC |
| Undisclosed reporting person | Feb. 1, 2011 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | March 20, 2009 | · | Initial filing | · | SEC |
| GlaxoSmithKline plc ×2 filings | Sept. 18, 2008 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Feb. 16, 2007 | · | Initial filing | · | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 filings | Jan. 19, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Dec. 15, 2004 | · | Initial filing | · | SEC |
| Undisclosed reporting person | June 29, 2004 | · | Initial filing | · | SEC |
| Undisclosed reporting person | June 24, 2002 | · | Initial filing | M&A / sale | SEC |
| Undisclosed reporting person | May 22, 2002 | · | Initial filing | · | SEC |
| Undisclosed reporting person | April 12, 2002 | · | Initial filing | M&A / sale | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 filings | Nov. 1, 2001 | · | Initial filing | M&A / sale | SEC |
| Undisclosed reporting person | May 14, 2001 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 52 insiders · 26 officers · 26 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | Sept. 1, 2026 S | 122,423 | 0 | 6 | $-17,083,502 |
| Surya N Mohapatra | Chairman, President & CEO | April 30, 2012 F | 243,713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | July 22, 2026 A | 33,478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | March 7, 2022 F | 98,981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | March 5, 2013 F | 126,722 | 0 | 0 | $0 |
| Michael E Prevoznik | SVP & General Counsel | Aug. 28, 2026 M | 36,557 | 0 | 6 | $-6,649,682 |
| Mark E Delaney | SVP & Chief Commercial Officer | July 28, 2026 S | 10,335 | 0 | 2 | $-1,864,971 |
| Karthik Kuppusamy | SVP, Clinical Solutions | July 22, 2026 L | 13,557 | 0 | 2 | $-2,167,772 |
| Patrick Plewman | SVP for Diagnostic Services | July 22, 2026 L | 15,293 | 0 | 4 | $-2,025,174 |
| Catherine T. Doherty | EVP, Regional Businesses | March 5, 2026 S | 67,122 | 0 | 8 | $-6,964,749 |
| Michael J Deppe | SVP, Corp. Controller & CAO | March 4, 2026 F | 35,196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | Sept. 24, 2024 F | 4,673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | March 7, 2022 F | 48,391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | Feb. 17, 2021 A | 29,045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | March 1, 2019 F | 6,261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | March 8, 2018 M | 31,757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | March 1, 2018 G | 37,760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | March 2, 2015 F | 11,837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | Feb. 13, 2014 A | 19,890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | March 31, 2013 F | 9,569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | Feb. 29, 2012 F | 89,232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | June 16, 2011 M | 47,150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | Feb. 12, 2007 A | 12,974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | Feb. 12, 2007 A | 31,079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | Feb. 12, 2007 A | · | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | Feb. 28, 2004 F | 49,609 | 0 | 0 | $0 |
| Timothy C Wentworth | Director | Oct. 1, 2026 A | 1,358 | 0 | 0 | $0 |
| Wright Lassiter III | Director | July 22, 2026 L | 10,323 | 0 | 0 | $0 |
| Vicky B Gregg | Director | July 22, 2026 A | 18,386 | 0 | 1 | $-239,700 |
| Robert B Carter | Director | July 22, 2026 L | 3,864 | 0 | 0 | $0 |
| Timothy L Main | Director | July 22, 2026 L | 22,460 | 0 | 0 | $0 |
| Luis Diaz | Director | May 20, 2026 A | 5,196 | 0 | 0 | $0 |
| Tracey Doi | Director | May 20, 2026 A | 7,748 | 0 | 0 | $0 |
| Timothy M Ring | Director | May 20, 2026 A | 31,140 | 0 | 0 | $0 |
| Gary M Pfeiffer | Director | May 20, 2026 A | 31,005 | 0 | 1 | $-270,317 |
| Gail R Wilensky | Director | May 17, 2023 A | 20,506 | 0 | 0 | $0 |
| Stephen H Rusckowski | Director | March 6, 2023 F | 389,597 | 0 | 0 | $0 |
| Helen Torley | Director | May 25, 2021 A | 6,260 | 0 | 0 | $0 |
| Daniel Stanzione | Director | Nov. 23, 2020 S | 28,349 | 0 | 0 | $0 |
| Jenne K Britell | Director | June 4, 2018 G | 14,479 | 0 | 0 | $0 |
| Jeffrey M Leiden | Director | May 29, 2018 S | 6,000 | 0 | 0 | $0 |
| John B Ziegler | Director | Feb. 22, 2017 S | 16,557 | 0 | 0 | $0 |
| John C Baldwin MD | Director | Aug. 12, 2015 S | 12,949 | 0 | 0 | $0 |
| William F Buehler | Director | Feb. 12, 2014 M | 26,225 | 0 | 0 | $0 |
| GSK plc | Director | Jan. 31, 2011 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | Director | May 6, 2010 A | 9,334 | 0 | 0 | $0 |
| William R Grant | Director | April 1, 2007 A | 3,334 | 0 | 0 | $0 |
| James F Flaherty III | Director | May 4, 2006 A | 1,667 | 0 | 0 | $0 |
| Kenneth D Brody | Director | April 28, 2004 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | Director | April 1, 2004 A | 2,627 | 0 | 0 | $0 |
| Denise M Morrison | · | May 20, 2026 A | 11,929 | 0 | 0 | $0 |
| FREEMAN KENNETH W/NJ | · | Dec. 14, 2004 F | 216,187 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 133 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IHF · iShares Trust | 3.75% | 212,725 SH | Sept. 11, 2026 | Daily |
| RW · EA Series Trust | 2.50% | 1,865 NS | July 31, 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.62% | 61,132 SH | Oct. 2, 2026 | Daily |
| FXH · First Trust Exchange-Traded AlphaDE… | 1.49% | 67,178 NS | July 31, 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1.27% | 11,113 SH | Oct. 2, 2026 | Daily |
| NUDV · Nushares ETF Trust | 1.09% | 2,338 NS | July 31, 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.97% | 637 NS | July 31, 2026 | N-PORT |
| SPLV · Invesco Exchange-Traded Fund Trust … | 0.88% | 263,082 SH | Oct. 2, 2026 | Daily |
| SPVM · Invesco Exchange-Traded Fund Trust | 0.78% | 4,469 SH | Oct. 2, 2026 | Daily |
| JOET · Virtus ETF Trust II | 0.78% | 8,139 NS | July 31, 2026 | N-PORT |
| ESMV · iShares Trust | 0.70% | 236 SH | Sept. 11, 2026 | Daily |
| QLV · FlexShares Trust | 0.63% | 4,452 NS | July 31, 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0.60% | 1,903 NS | July 31, 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0.46% | 369,448 NS | July 31, 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0.43% | 8,600 NS | July 31, 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.43% | 8,453 NS | July 31, 2026 | N-PORT |
| IYH · iShares Trust | 0.41% | 64,629 SH | Sept. 11, 2026 | Daily |
| VOE · VANGUARD INDEX FUNDS | 0.40% | 711,079 SH | Aug. 19, 2026 | Daily |
| FTA · First Trust Exchange-Traded AlphaDE… | 0.38% | 22,688 NS | July 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.37% | 52,313 NS | July 31, 2026 | N-PORT |
| IMCV · iShares Trust | 0.36% | 18,030 SH | Sept. 11, 2026 | Daily |
| SUSA · iShares Trust | 0.34% | 59,240 SH | Sept. 11, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.34% | 330,273 SH | Aug. 19, 2026 | Daily |
| IXJ · iShares Trust | 0.32% | 58,047 SH | Sept. 11, 2026 | Daily |
| DFLV · Dimensional ETF Trust | 0.30% | 87,905 NS | July 31, 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.30% | 19,944 NS | July 31, 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.30% | 2,178 NS | July 31, 2026 | N-PORT |
| EQIN · Columbia ETF Trust I | 0.27% | 3,540 NS | July 31, 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0.26% | 9,337 NS | July 31, 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0.26% | 27,542 NS | July 31, 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0.25% | 7,574,000 | Oct. 2, 2026 | Daily |
| IWS · iShares Trust | 0.25% | 165,299 SH | Sept. 11, 2026 | Daily |
| ESUM · Strategy Shares | 0.24% | 1,901 NS | July 31, 2026 | N-PORT |
| SIZE · iShares Trust | 0.24% | 4,359 SH | Sept. 11, 2026 | Daily |
| VO · VANGUARD INDEX FUNDS | 0.23% | 2,398,948 SH | Aug. 19, 2026 | Daily |
| VFMV · VANGUARD WELLINGTON FUND | 0.22% | 4,307 SH | Aug. 19, 2026 | Daily |
| RSP · Invesco Exchange-Traded Fund Trust | 0.20% | 829,766 SH | Oct. 2, 2026 | Daily |
| ACWV · iShares, Inc. | 0.20% | 28,973 SH | Sept. 11, 2026 | Daily |
| EUSA · iShares, Inc. | 0.19% | 16,140 SH | Sept. 11, 2026 | Daily |
| FAB · First Trust Exchange-Traded AlphaDE… | 0.19% | 1,371 NS | July 31, 2026 | N-PORT |
| IWR · iShares Trust | 0.19% | 452,857 SH | Sept. 11, 2026 | Daily |
| IMCB · iShares Trust | 0.18% | 12,959 SH | Sept. 11, 2026 | Daily |
| MTUM · iShares Trust | 0.16% | 168,369 SH | Sept. 11, 2026 | Daily |
| DFVX · Dimensional ETF Trust | 0.16% | 3,609 NS | July 31, 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.15% | 97,399 NS | July 31, 2026 | N-PORT |
| ESLG · Strategy Shares | 0.15% | 146 NS | July 31, 2026 | N-PORT |
| XOEF · iShares Trust | 0.15% | 140 SH | Sept. 11, 2026 | Daily |
| CATH · Global X Funds | 0.12% | 6,867 NS | July 31, 2026 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.12% | 165,000 | Oct. 1, 2026 | Daily |
| ROUS · Lattice Strategies Trust | 0.12% | 3,633 NS | July 31, 2026 | N-PORT |
| SPMO · Invesco Exchange-Traded Fund Trust … | 0.11% | 115,253 SH | Oct. 2, 2026 | Daily |
| EVUS · iShares Trust | 0.11% | 1,865 SH | Sept. 11, 2026 | Daily |
| VIG · VANGUARD SPECIALIZED FUNDS | 0.10% | 625,384 SH | Aug. 19, 2026 | Daily |
| VYM · VANGUARD WHITEHALL FUNDS | 0.10% | 440,583 SH | Aug. 19, 2026 | Daily |
| DGRO · iShares Trust | 0.10% | 179,879 SH | Sept. 11, 2026 | Daily |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.09% | 3,271 SH | Oct. 2, 2026 | Daily |
| PFM · Invesco Exchange-Traded Fund Trust | 0.09% | 3,153 SH | Oct. 2, 2026 | Daily |
| VTV · VANGUARD INDEX FUNDS | 0.09% | 1,051,572 SH | Aug. 19, 2026 | Daily |
| DXUV · Dimensional ETF Trust | 0.09% | 2,092 NS | July 31, 2026 | N-PORT |
| CRBN · iShares Trust | 0.09% | 4,406 SH | Sept. 11, 2026 | Daily |
| DCOR · Dimensional ETF Trust | 0.09% | 12,279 NS | July 31, 2026 | N-PORT |
| IVE · iShares Trust | 0.09% | 183,297 SH | Sept. 11, 2026 | Daily |
| IUSV · iShares Trust | 0.08% | 97,344 SH | Sept. 11, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.08% | 167,227 NS | July 31, 2026 | N-PORT |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.08% | 25,423 SH | Aug. 19, 2026 | Daily |
| CHRI · Global X Funds | 0.08% | 27 NS | July 31, 2026 | N-PORT |
| IQSU · New York Life Investments ETF Trust | 0.08% | 1,095 NS | July 31, 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.08% | 3,155 SH | Oct. 2, 2026 | Daily |
| SUSL · iShares Trust | 0.08% | 3,907 SH | Sept. 11, 2026 | Daily |
| ILCV · iShares Trust | 0.07% | 4,337 SH | Sept. 11, 2026 | Daily |
| DSI · iShares Trust | 0.07% | 16,854 SH | Sept. 11, 2026 | Daily |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.07% | 66,643 SH | Aug. 19, 2026 | Daily |
| IWD · iShares Trust | 0.07% | 245,078 SH | Sept. 11, 2026 | Daily |
| HDUS · Lattice Strategies Trust | 0.07% | 586 NS | July 31, 2026 | N-PORT |
| EGLE · Global X Funds | 0.06% | 6 NS | July 31, 2026 | N-PORT |
| GLBL · Pacer Funds Trust | 0.06% | 3 NS | July 31, 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.06% | 24,838 SH | Oct. 2, 2026 | Daily |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.06% | 24,491 SH | Oct. 2, 2026 | Daily |
| DFSU · Dimensional ETF Trust | 0.05% | 5,056 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.05% | 26,447 NS | July 31, 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.05% | 9,857 SH | Oct. 2, 2026 | Daily |
| TOPC · iShares Trust | 0.05% | 68 SH | Sept. 11, 2026 | Daily |
| XVV · iShares Trust | 0.04% | 1,285 SH | Sept. 11, 2026 | Daily |
| XYLD · Global X Funds | 0.04% | 6,096 NS | July 31, 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.04% | 3,119 SH | Oct. 2, 2026 | Daily |
| BKLC · BNY Mellon ETF Trust | 0.04% | 9,574 NS | July 31, 2026 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.04% | 15,319 NS | July 31, 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0.04% | 2,875,103 SH | Aug. 19, 2026 | Daily |
| VV · VANGUARD INDEX FUNDS | 0.04% | 129,285 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.04% | 24,972 SH | Aug. 19, 2026 | Daily |
| TOV · EA Series Trust | 0.04% | 426 NS | July 31, 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0.04% | 5,593 NS | July 31, 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0.04% | 1,876 NS | July 31, 2026 | N-PORT |
| XYLG · Global X Funds | 0.04% | 109 NS | July 31, 2026 | N-PORT |
| XCLR · Global X Funds | 0.04% | 6 NS | July 31, 2026 | N-PORT |
| IVV · iShares Trust | 0.04% | 1,392,389 SH | Sept. 11, 2026 | Daily |
| PBP · Invesco Exchange-Traded Fund Trust | 0.04% | 655 SH | Oct. 2, 2026 | Daily |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.04% | 19,201 SH | Oct. 2, 2026 | Daily |
| XTR · Global X Funds | 0.04% | 8 NS | July 31, 2026 | N-PORT |
| ILCB · iShares Trust | 0.04% | 2,144 SH | Sept. 11, 2026 | Daily |
| XRMI · Global X Funds | 0.04% | 82 NS | July 31, 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.04% | 33,588 NS | July 31, 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.04% | 417 NS | July 31, 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0.04% | 2,663 NS | July 31, 2026 | N-PORT |
| IWB · iShares Trust | 0.04% | 76,198 SH | Sept. 11, 2026 | Daily |
| VOXP · Advisors Series Trust | 0.04% | 9 NS | July 31, 2026 | N-PORT |
| IYY · iShares Trust | 0.04% | 4,688 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.03% | 30,298 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.03% | 141,099 SH | Sept. 11, 2026 | Daily |
| PHDG · Invesco Actively Managed Exchange-T… | 0.03% | 88 SH | Oct. 2, 2026 | Daily |
| HCMT · Direxion Shares ETF Trust | 0.03% | 772 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.03% | 3,515,122 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.03% | 18,213 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.03% | 9,300 SH | Aug. 19, 2026 | Daily |
| SPXL · Direxion Shares ETF Trust | 0.03% | 8,650 NS | July 31, 2026 | N-PORT |
| URTH · iShares, Inc. | 0.03% | 10,177 SH | Sept. 11, 2026 | Daily |
| TILT · FlexShares Trust | 0.03% | 2,686 NS | July 31, 2026 | N-PORT |
| TOK · iShares Trust | 0.03% | 292 SH | Sept. 11, 2026 | Daily |
| ACWI · iShares Trust | 0.03% | 36,161 SH | Sept. 11, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.02% | 95,097 SH | Aug. 19, 2026 | Daily |
| DYNF · BlackRock ETF Trust | 0.02% | 34,844 SH | Sept. 11, 2026 | Daily |
| GTO · Invesco Actively Managed Exchange-T… | 0.00% | 1,000 | Sept. 30, 2026 | Daily |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BND · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| VCRB · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| VSDB · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| VCEB · VANGUARD WORLD FUND | · | · | July 30, 2026 | Daily |
DGX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 23 analysts
BUY
Median target
$250.00
+7.1%
6 26.1%
Strong Buy
7 30.4%
Buy
10 43.5%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
15 analysts · 2026-10-04Mean target $247.73 +6.2%
Now
Current price $233.33
Low$204.00
Mean$247.73
High$265.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | · |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | · |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | · |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| HIMS | · | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| CHE | · | 23.3 | 4.1% | 10.5% | 24.4% | · |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Jul 23, 2026